Century Therapeutics (IPSC) Expected to Post Earnings on Thursday

Century Therapeutics (NASDAQ:IPSC) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Century Therapeutics to announce earnings of ($0.11) per share and revenue of $2.1670 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Wednesday, May 13th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. On average, analysts expect Century Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Century Therapeutics Price Performance

Shares of Century Therapeutics stock opened at $2.06 on Wednesday. The company has a 50 day simple moving average of $2.20 and a two-hundred day simple moving average of $2.23. The firm has a market cap of $371.52 million, a PE ratio of -1.81 and a beta of 1.57. Century Therapeutics has a 1 year low of $0.43 and a 1 year high of $3.04.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. bought a new position in Century Therapeutics in the 4th quarter worth $1,829,000. Geode Capital Management LLC boosted its stake in shares of Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock valued at $454,000 after purchasing an additional 10,806 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Century Therapeutics by 64.1% during the 3rd quarter. Citadel Advisors LLC now owns 360,825 shares of the company’s stock valued at $180,000 after purchasing an additional 140,891 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Century Therapeutics by 59.2% during the third quarter. Two Sigma Investments LP now owns 911,446 shares of the company’s stock valued at $454,000 after buying an additional 338,902 shares during the period. Finally, Squarepoint Ops LLC increased its position in shares of Century Therapeutics by 483.1% during the third quarter. Squarepoint Ops LLC now owns 236,053 shares of the company’s stock valued at $118,000 after buying an additional 195,573 shares during the period. 50.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Wall Street Zen cut shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Mizuho began coverage on Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Finally, HC Wainwright boosted their target price on Century Therapeutics from $2.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Century Therapeutics currently has an average rating of “Hold” and a consensus target price of $4.75.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.